Table 3.
Univariate and multivariate prognostic analyses of the patients (n = 79)
| Correlative factor | Number of cases |
Kaplan-Meier univariate analysis |
Cox multivariate analysis |
||||
| mPFS (mo) | 95%CI | P-value | Sig | EXP(B) | 95%CI | ||
| Interventional therapy | 0.00049 | 0.00048 | 0.26 | 0.174-0.612 | |||
| Chemoembolization | 37 | 4.5 | 3.3-5.7 | ||||
| Chemoembolization combined with HAIC | 42 | 8.0 | 7.2-8.8 | ||||
| Grading of physical condition | 0.00014 | 0.312 | 1.525 | 0.674-3.452 | |||
| PS = 0 | 40 | 8.9 | 6.2-11.5 | ||||
| PS = 1 | 39 | 4.5 | 3.7-5.2 | ||||
| Vascular invasion1 | 0.00047 | 0.050 | 1.963 | 0.989-3.898 | |||
| No | 52 | 7.9 | 7.3-8.5 | ||||
| Yes | 27 | 3.8 | 2.7-4.8 | ||||
| BCLC Stage2 | 0.00051 | 0.003 | 3.083 | 1.479-6.426 | |||
| Stage C | 30 | 3.8 | 3.0-4.6 | ||||
| Stage A or B | 39 | 9.3 | 6.7-11.9 | ||||
| AFP (ng/mL) | 0.03 | 0.488 | 1.255 | 0.660-2.386 | |||
| < 400 | 52 | 7.3 | 5.8-8.8 | ||||
| ≥ 400 | 27 | 4.5 | 2.1-7.0 | ||||
| Sum of tumor target lesion diameter (cm) | 0.00011 | 0.326 | 1.449 | 0.691-3.338 | |||
| ≤ 10 | 45 | 7.8 | 6.1-9.5 | ||||
| > 10 | 34 | 4.3 | 3.2-5.3 | ||||
| Serum albumin (g/L) | 0.027 | 0.27 | 0.628 | 0.275-1.434 | |||
| < 35 | 7 | 4.3 | 3.0-5.6 | ||||
| ≥ 35 | 72 | 7.3 | 5.9-8.6 | ||||
1
Venous invasion refers to portal vein or hepatic vein tumor thrombosis, APVS;
2
BCLC staging did not include patients who relapsed after surgery. PFS: Progression free survival; mPFS: Median progression free survival; AFP: Alpha-fetoprotein; HAIC: Hepatic arterial infusion chemotherapy; BCLC: Barcelona Clinic Liver Cancer staging.